Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes.
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D000943:Antigens, Differentiation / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D003602:Cytotoxicity, Immunologic; D007111:Immunity, Cellular; D007116:Immunization, Passive; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D051379:Mice; D011971:Receptors, Immunologic / Q000032:analysis; D017474:Receptors, Laminin; D011994:Recombinant Proteins / Q000627:therapeutic use; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*
D000943:Antigens, Differentiation; D000954:Antigens, Surface; D007376:Interleukin-2; D011971:Receptors, Immunologic; D017474:Receptors, Laminin; D011994:Recombinant Proteins